Creative Planning Bristol Myers Squibb CO Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Creative Planning holds 490,783 shares of BMY stock, worth $27.6 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

490,783

Previous 531,970 7.74%

Holding current value

$27.6 Million

Previous $22.1 Million 14.96%

% of portfolio

0.03%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	SELL	$39.66 - $51.75 $1.63 Million - $2.13 Million	-41,187 Reduced 7.74%	490,783 $25.4 Million
Q2 2024 Aug 15, 2024	BUY	$40.25 - $52.99 $6 Million - $7.9 Million	149,088 Added 38.94%	531,970 $22.1 Million
Q1 2024 May 10, 2024	BUY	$47.98 - $54.4 $1.97 Million - $2.23 Million	40,960 Added 11.98%	382,882 $20.8 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $1.02 Million - $1.22 Million	-21,110 Reduced 5.81%	341,922 $17.5 Million
Q3 2023 Nov 16, 2023	BUY	$57.89 - $64.73 $1.06 Million - $1.18 Million	18,243 Added 5.29%	363,032 $21.1 Million
Q2 2023 Jul 21, 2023	BUY	$63.71 - $70.74 $1.16 Million - $1.29 Million	18,214 Added 5.58%	344,789 $22 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $251,406 - $285,151	-3,826 Reduced 1.16%	326,575 $22.6 Million
Q4 2022 Feb 10, 2023	BUY	$68.48 - $81.09 $1.21 Million - $1.44 Million	17,705 Added 5.66%	330,401 $23.8 Million
Q3 2022 Nov 03, 2022	BUY	$0.13 - $76.84 $401 - $237,435	3,090 Added 1.0%	312,696 $22.2 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $2.94 Million - $3.24 Million	40,506 Added 15.05%	309,606 $23.8 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $408,657 - $490,016	6,647 Added 2.53%	269,100 $19.7 Million
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $443,841 - $517,415	-8,276 Reduced 3.06%	262,453 $16.4 Million
Q3 2021 Nov 10, 2021	SELL	$59.17 - $69.31 $242,478 - $284,032	-4,098 Reduced 1.49%	270,729 $16 Million
Q2 2021 Aug 04, 2021	SELL	$61.91 - $67.42 $3.87 Million - $4.21 Million	-62,457 Reduced 18.52%	274,827 $18.4 Million
Q1 2021 Apr 30, 2021	SELL	$59.34 - $66.74 $137,134 - $154,236	-2,311 Reduced 0.68%	337,284 $21.3 Million
Q4 2020 Jan 29, 2021	BUY	$57.74 - $65.43 $878,802 - $995,844	15,220 Added 4.69%	339,595 $21.1 Million
Q3 2020 Nov 05, 2020	BUY	$57.43 - $63.64 $1.11 Million - $1.23 Million	19,276 Added 6.32%	324,375 $19.6 Million
Q2 2020 Jul 23, 2020	BUY	$54.82 - $64.09 $22,531 - $26,340	411 Added 0.13%	305,099 $17.9 Million
Q1 2020 May 05, 2020	SELL	$46.4 - $67.43 $914,358 - $1.33 Million	-19,706 Reduced 6.07%	304,688 $17 Million
Q4 2019 Jan 30, 2020	BUY	$49.21 - $64.19 $2.02 Million - $2.64 Million	41,139 Added 14.52%	324,394 $20.8 Million
Q3 2019 Nov 01, 2019	BUY	$42.77 - $50.71 $14,156 - $16,785	331 Added 0.12%	283,255 $14.4 Million
Q2 2019 Jul 26, 2019	SELL	$44.62 - $49.34 $188,162 - $208,066	-4,217 Reduced 1.47%	282,924 $12.8 Million
Q1 2019 Apr 24, 2019	SELL	$45.12 - $53.8 $375,353 - $447,562	-8,319 Reduced 2.82%	287,141 $13.7 Million
Q4 2018 Feb 01, 2019	SELL	$48.76 - $63.23 $12,921 - $16,755	-265 Reduced 0.09%	295,460 $15.4 Million
Q3 2018 Oct 25, 2018	BUY	$55.19 - $62.25 $902,963 - $1.02 Million	16,361 Added 5.86%	295,725 $18.4 Million
Q2 2018 Jul 20, 2018	SELL	$50.53 - $62.98 $511,666 - $637,735	-10,126 Reduced 3.5%	279,364 $15.5 Million
Q1 2018 Apr 18, 2018	SELL	$59.92 - $68.98 $787,049 - $906,052	-13,135 Reduced 4.34%	289,490 $18.3 Million
Q4 2017 Jan 17, 2018	BUY	$59.94 - $65.35 $1.93 Million - $2.1 Million	32,141 Added 11.88%	302,625 $18.5 Million
Q3 2017 Oct 17, 2017	BUY	$55.23 - $63.74 $14.9 Million - $17.2 Million	270,484	270,484 $17.2 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Bristol Myers Squibb CO Transaction History